 SHANGHAI and GAITHERSBURG, Md., June 30, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it was ranked among the top companies by leading global financial publication Institutional Investor in both the Honored Companies and Best CFO categories, according to its 2021 All-Asia Executive Team survey. 